Sanofi’s drug ingredients spinoff Euroapi has made short work of its Hungarian manufacturing snafu—though not without incurring a sizable hit to its top line, one group of analysts contends.
Enforcement Report - Week of January 18, 2023
Enforcement Report - Week of June 15, 2022
Enforcement Report - Week Of June 01, 2022
The shuttering of Teva’s long troubled manufacturing facility in Irvine, California, may create shortages of up to 24 generic sterile injectable drugs, including five essential medications of which the company supplied more than 15% of the market last year, according to an industry group.
Enforcement Report - Week of March 23, 2022
Enforcement Report - Week of November 17, 2021
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Enforcement Report - Week of August 25, 2021
Enforcement Report - Week of March 11, 2020